Actor Christopher Biggins has revealed he is using weight loss jabs as he needed to lose weight after having surgery on his ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

New NHS data suggests weight-loss jabs like Mounjaro could reduce sick days by a third and save taxpayers £5bn a year. But ...

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh ...

THE NHS is set to dish out Mounjaro prescriptions to more patients, as private clinics prepare to double their prices from ...

The company said Friday that it received FDA approval for a new Wegovy indication as a treatment of a fatty liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH, in adults ...

Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy, warned it is 'crucial' to transition under ...

The company said it was reviewing Mounjaro pricing with other governments and expected to make similar adjustments in certain ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Discover key highlights in healthcare stocks, including UnitedHealth's surge after a Buffett stake, Eli Lilly lawsuits, Trump pharma tariffs & Bayer's ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...